Diversified Trust Co Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Diversified Trust Co lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% in the fourth quarter, Holdings Channel reports. The firm owned 34,455 shares of the biopharmaceutical company’s stock after buying an additional 1,019 shares during the period. Diversified Trust Co’s holdings in Gilead Sciences were worth $3,183,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $25,000. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $33,000. Cedar Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the last quarter. Finally, Friedenthal Financial acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $50,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.7 %

Shares of NASDAQ GILD opened at $90.63 on Wednesday. The stock has a market cap of $112.95 billion, a P/E ratio of 1,007.00, a PEG ratio of 2.24 and a beta of 0.18. The business’s fifty day simple moving average is $91.91 and its 200-day simple moving average is $82.98. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the company earned $2.29 EPS. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.40%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 8,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $91.96, for a total value of $781,660.00. Following the completion of the transaction, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 453,734 shares of company stock valued at $41,902,086. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GILD. Mizuho boosted their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Piper Sandler upped their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Barclays boosted their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Finally, Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target for the company. Twelve analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.